Royalty Pharma plc (NASDAQ:RPRX – Get Rating) major shareholder 1978 Sicaf Sif S.A. – Gg St Gg sold 250,000 shares of Royalty Pharma stock in a transaction on Wednesday, September 7th. The shares were sold at an average price of $42.53, for a total value of $10,632,500.00. Following the completion of the transaction, the insider now owns 22,674,176 shares in the company, valued at approximately $964,332,705.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
1978 Sicaf Sif S.A. – Gg St Gg also recently made the following trade(s):
- On Thursday, August 25th, 1978 Sicaf Sif S.A. – Gg St Gg sold 1,994 shares of Royalty Pharma stock. The shares were sold at an average price of $44.00, for a total value of $87,736.00.
Royalty Pharma Stock Up 1.5 %
Shares of NASDAQ RPRX opened at $43.63 on Friday. Royalty Pharma plc has a 1 year low of $34.86 and a 1 year high of $44.75. The firm has a market cap of $26.49 billion, a price-to-earnings ratio of 56.66, a PEG ratio of 1.15 and a beta of 0.30. The company has a debt-to-equity ratio of 0.68, a quick ratio of 19.22 and a current ratio of 19.22. The stock’s 50-day simple moving average is $43.13 and its 200-day simple moving average is $41.29.
Royalty Pharma Dividend Announcement
Wall Street Analyst Weigh In
RPRX has been the topic of several research reports. Tigress Financial raised their price objective on Royalty Pharma from $52.00 to $57.00 and gave the company a “buy” rating in a research report on Thursday, July 14th. UBS Group initiated coverage on Royalty Pharma in a research report on Monday, June 13th. They issued a “buy” rating and a $47.00 price objective on the stock. Morgan Stanley raised their price objective on Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a research report on Monday, August 8th. Finally, Citigroup raised their price objective on Royalty Pharma from $50.00 to $60.00 in a research report on Thursday, July 28th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $53.43.
Hedge Funds Weigh In On Royalty Pharma
Hedge funds have recently bought and sold shares of the company. TD Asset Management Inc. grew its stake in Royalty Pharma by 8.4% in the fourth quarter. TD Asset Management Inc. now owns 167,407 shares of the biopharmaceutical company’s stock worth $6,671,000 after purchasing an additional 12,915 shares in the last quarter. Ensign Peak Advisors Inc acquired a new position in Royalty Pharma in the fourth quarter worth about $2,030,000. Dimensional Fund Advisors LP grew its stake in Royalty Pharma by 43.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 230,201 shares of the biopharmaceutical company’s stock worth $9,174,000 after purchasing an additional 69,686 shares in the last quarter. Greytown Advisors Inc. grew its stake in Royalty Pharma by 19.3% in the fourth quarter. Greytown Advisors Inc. now owns 126,883 shares of the biopharmaceutical company’s stock worth $5,056,000 after purchasing an additional 20,562 shares in the last quarter. Finally, FCF Advisors LLC acquired a new position in Royalty Pharma in the first quarter worth about $498,000. 54.94% of the stock is currently owned by institutional investors and hedge funds.
Royalty Pharma Company Profile
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
- Get a free copy of the StockNews.com research report on Royalty Pharma (RPRX)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.